Technetium-99m Market Report 2025

The technetium-99m market size has grown strongly in recent years. It will grow from $4.52 billion in 2024 to $4.75 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to the expanding applications of nuclear medicine, rising demand for cancer and cardiac diagnostics, increased dependence on molybdenum-99 supply, growing demand for radiopharmaceuticals, and the heightened use of imaging in clinical trials.

The technetium-99m market size is expected to see steady growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth projected for the forecast period can be attributed to expanding nuclear imaging capabilities, an increasing geriatric population, a higher volume of diagnostics, rising cancer incidence, and growing adoption of hybrid imaging systems. Key trends during this period include the development of sustainable isotope technologies, non-reactor-based production methods, advancements in radiopharmaceutical technologies, integration with artificial intelligence, and innovations in radiopharmaceutical manufacturing.

The growing demand for diagnostic imaging procedures is expected to drive the growth of the technetium-99m market moving forward. Diagnostic imaging procedures involve medical techniques that create visual representations of the body’s interior, assisting doctors in diagnosing and sometimes guiding treatment for various conditions. This rising demand is largely due to the increasing prevalence of chronic diseases that require early and accurate diagnosis. Technetium-99m supports diagnostic imaging by enabling doctors to visualize organ and tissue functions with high precision, using its radioactive properties to produce detailed images during nuclear medicine scans. For example, according to NHS England, a UK government department, 45 million imaging tests were performed in England in the year ending March 2023, reflecting a 2.2% increase compared to the 44 million tests conducted the previous year. Thus, the rising demand for diagnostic imaging is fueling the technetium-99m market’s growth.

Companies in the technetium-99m market are focusing on developing innovative solutions such as advanced radiopharmaceutical imaging agents to improve the accuracy and accessibility of diagnostic imaging for complex medical conditions. These agents are special compounds labeled with radioactive materials that help doctors visualize internal body structures using imaging techniques. For instance, in June 2024, Serac Healthcare Limited, a UK-based clinical radiopharmaceutical company, received Fast Track Designation from the US FDA for 99mTc-maraciclatide, an innovative SPECT-CT imaging agent designed to visualize and diagnose superficial peritoneal endometriosis in women aged 16 and older. This agent is a technetium-99m-labeled targeted peptide that binds to integrins overexpressed in endometriosis lesions, allowing clear visualization of disease sites during SPECT-CT scans. It offers a non-invasive diagnostic alternative to laparoscopic procedures, providing a safer and more accessible diagnostic option for women suspected of having endometriosis. Utilizing the favorable imaging characteristics of technetium-99m, including its ideal half-life and gamma emission energy, this agent delivers high-quality diagnostic images while minimizing radiation exposure. This innovation is expected to improve diagnostic accuracy and support better treatment decisions in endometriosis management, while broadening the clinical use of technetium-99m-based imaging in women’s health.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired ARTMS Inc. for an undisclosed sum. Through this acquisition, Telix aims to strengthen its control over the supply chain for key medical isotopes such as technetium-99m by integrating ARTMS’s cyclotron-based radioisotope production technology. This move is intended to support large-scale, cost-effective, and reliable production of diagnostic and therapeutic isotopes within Telix’s radiopharmaceutical portfolio. ARTMS Inc. is a Canada-based company specializing in advanced cyclotron technologies for producing medical radioisotopes including technetium-99m.

Major players in the technetium-99m market are Cardinal Health Inc., Siemens Healthineers AG, Philips Healthcare, GE Healthcare Technologies Inc., BWX Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., China Isotope & Radiation Corporation (CIRC), Jubilant Pharma Limited, Curium Pharma LLC, Eckert & Ziegler Strahlen, Telix Pharmaceuticals Limited, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd., Advanced Cyclotron Systems Inc., Cyclopharm Limited, SHINE Technologies LLC, Medi-Radiopharma Kft., and SDS Lifesciences Pvt Ltd.

North America was the largest region in the technetium-99m market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in technetium-99m report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the technetium-99m market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The technetium-99m market includes revenues earned by entities by providing services such as diagnostic imaging, functional imaging, medical diagnostic imaging, cardiac imaging, and cancer detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The technetium-99m market also includes sales of technetium-99m sestamibi, mercaptoacetyltriglycine, hexamethylpropyleneamine oxime, technetium-99m pertechnetate, and diethylenetriamine pentaacetic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The technetium-99m market research report is one of a series of new reports that provides technetium-99m market statistics, including technetium-99m industry global market size, regional shares, competitors with a technetium-99m market share, technetium-99m market segments, market trends and opportunities, and any further data you may need to thrive in the technetium-99m industry. This technetium-99m market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Technetium-99m (Tc-99m) is a radioactive isotope of technetium commonly used in nuclear medicine for diagnostic imaging. It emits gamma rays that can be detected by a gamma camera, enabling visualization of internal organs and structures. With a short half-life of approximately 6 hours, Tc-99m limits patient radiation exposure while delivering clear imaging results.

The primary products related to technetium-99m include radiopharmaceuticals, diagnostic kits, and generators. Radiopharmaceuticals are radioactive compounds used in medical imaging and therapy for diagnosis or treatment. These are available in various formulations such as liquid, solid, and freeze-dried forms. Applications span single photon emission computed tomography (SPECT), positron emission tomography (PET), oncology, cardiology, neurology, and more. The key end users include hospitals, diagnostic imaging centers, research laboratories, specialized clinics, and other healthcare facilities.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.